Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A chronic gastric motility disorder in which the stomach does not empty food as quickly as it should, gastroparesis results in potentially serious forms of heartburn, nausea, vomiting and bloating for millions of patients in the U.S. “We are very pleased to announce that we have randomized the first patient in our PCS12852 Phase 2A study for the treatment of patients with gastroparesis,” said Dr. Sian Bigora, chief development officer at Processa. “In our previous Phase 2A clinical study in constipation patients, the gastric emptying rate significantly improved while on PCS12852 with no safety concerns. We expect this study to show a similar effect on the gastric emptying rate as well as provide us with valuable data on the effect of PCS12852 on the symptoms associated with gastroparesis in both diabetic and idiopathic gastroparesis patients. Information from the study will then be used to further design our Phase 2B study.”
To view the full press release, visit https://ibn.fm/5kxDC
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.